<DOC>
	<DOCNO>NCT02895945</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety BAX 802 male congenital hemophilia A ( CHA ) inhibitor undergo major minor elective surgical , dental , invasive procedure .</brief_summary>
	<brief_title>BAX 802 CHA With Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Participant ≥ 18 ≤ 65 year old time screen 2 . Participant provide sign informed consent 3 . Participant severe ( Factor VIII ( FVIII ) level &lt; 1 % ) moderately severe ( FVIII level ≤ 2 % ) Congenital Hemophilia A ( CHA ) inhibitor human FVIII , test screening central laboratory 4 . Participant require elective surgery invasive procedure 5 . Participant currently receive receive ( &lt; 30 day ) immune tolerance induction ( ITI ) therapy 6 . Participant Karnofsky performance score ≥ 60 7 . Participant human immunodeficiency virus negative ( HIV ) ; HIV+ stable disease CD4+ count ≥ 200 cells/mm^3 screen 8 . Participant hepatitis C virus negative ( HCV ) antibody polymerase chain reaction ( PCR ) testing ; HCV+ chronic stable hepatitis disease 9 . Participant willing able comply requirement protocol . 1 . The participant require emergency surgery 2 . The participant 's weight &lt; 35 kg &gt; 120 kg 3 . Clinically symptomatic liver disease ( eg , ≥ 5 X upper limit normal alanine aminotransferase [ ALT ] , confirm central laboratory screening , clinical evidence portal hypertension , severe hypoalbuminemia document prothrombin time/international normalize ratio ( PT/INR ) &gt; 1.5 ) 4 . Clinically symptomatic renal disease ( serum creatinine &gt; 2.0 mg/dL ) , confirmed central laboratory screen 5 . Antiporcine inhibitor &gt; 10 BU prior surgery 6 . Platelet count &lt; 100,000/μL 7 . Participant another active coagulation disorder hemophilia A , per medical history Planned use αinterferon without ribavarin HCV infect patient plan use protease inhibitor HIV infect patient . Patients currently take medication ≥ 30 day eligible 9 . Known hypersensitivity recombinant porcine factor VIII ( rpFVIII ) , hamster murine proteins 10 . Participant expose investigational product ( IP ) within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study 11 . Unable tolerate quantity blood drawn protocol procedures 12 . Participant family member employee investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>